A Clinical Trial of Fruquintinib in Patients With Advanced Non-small Cell Lung Cancer

Phase 2 Completed 91 enrolled Hutchison Medipharma Limited Shanghai Chest Hospital · collab

RandomizedParallel-groupDouble-blindTreatment

Summary

This is a randomized, double-blind, placebo-controlled, multi-center Phase II clinical trial to evaluate the efficacy and safety of Fruquintinib plus best supportive care in patients with advanced non-squamous non-small cell lung cancer who failed to second-line standard chemotherapy.

Timeline

Start: 2014-05-29
Primary completion: 2015-08-07
Completion: 2017-02-10

Outcome

Met primary endpoint

paper Conclusion Third- and fourth-line fruquintinib for advanced NSCLC was superior to placebo and had an acceptable safety profile. PMID 29528793 ↗

release “successfully achieved the primary endpoint in the second proof-of-concept (“POC”) trial of fruquintinib in patients with advanced non-squamous non-small cell lung cancer (“NSCLC”) in China.” hutch-med.com ↗

release “Fruquintinib in third-line NSCLC met the primary efficacy endpoint of PFS” hutch-med.com ↗

Publications

Lu S, Chang J, Liu X, Shi J, Lu Y, Li W, Yang JJ, Zhou J, Wang J, An T, Yang L, Liu Z, Zhou X, Chen M, Hua Y, Su W. Randomized, Double-Blind, Placebo-Controlled, Multicenter Phase II Study of Fruquintinib After Two Prior Chemotherapy Regimens in Chinese Patients With Advanced Nonsquamous Non-Small-Cell Lung Cancer. J Clin Oncol. 2018 Apr 20;36(12):1207-1217. doi: 10.1200/JCO.2017.76.7145. Epub 2018 Mar 12.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Fruquintinib	Small molecule	5 mg	Oral